Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bimokalner
- Development stage
- Phase 2
- Lead developer
- Acousia Therapeutics
- Modality
- Small Molecules
- Administration
- Transtympanic
01
Overview
Bimokalner is an investigational small molecule drug developed by Acousia Therapeutics for the prevention and treatment of hearing loss, particularly cisplatin-induced hearing loss in cancer patients. It acts as a selective agonist (stimulator) of the voltage-gated potassium channel Kv7.4 (also known as KCNQ4), which plays a key role in regulating neuronal excitability and maintaining cochlear function. Bimokalner is administered via transtympanic injection to deliver the drug directly to the middle ear, aiming to protect inner ear structures from damage caused by ototoxic agents such as cisplatin. The drug is currently in Phase 2 clinical trials for hearing loss prevention and has also been studied preclinically for aminoglycoside-induced deafness[1][3][4][5].
- Other names
- bimokalnerum
02
Targets
KCNQ4 (Potassium channel subfamily KQT member 4)
Beyond the preview
Go deeper on bimokalner.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bimokalner.